Gilead: HIV Franchise Woes Highlight Cancer Follies
Gilead’s HIV franchise generated $19.612B in 2024, but faces future funding challenges. Learn why GILD stock is a "Hold" amid ...
STAT3d
Rollout of ‘miracle’ HIV prevention drug is threatened by Trump cuts to global AIDS relief program
PEPFAR had been set to lead the rollout of Gilead Science's lenacapavir, which has been hailed as a "miracle" of HIV ...
CSRWire2d
Discovering a Breakthrough: Gilead’s Long-Standing Commitment to Helping Change the Course of HIV
Tomas Cihlar knew all too well that despite initial successes with combination treatment, HIV was firmly holding ground ...
Gilead’s HIV Treatments Could Face Headwinds. Why the Stock Will Still Rise.
Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...
Major HIV drug maker to cut nearly 150 Bay Area jobs
On the same day the Trump Administration unceremoniously shut down the U.S. Department of Health and Human Services Regional ...
Fierce Pharma9d
Potential federal budget cuts won't rock Gilead's HIV boat too much: analysts
News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...
Winners and wishers: 9 potential Bay Area drug approvals coming this year
Three other Bay Area companies — Mirum Therapeutics Inc. (Nasdaq: MIRM), Soleno Therapeutics Inc. (Nasdaq: SLNO) and Exelixis ...
CSRWire9d
Gilead Sciences: Using Lessons From the HIV Epidemic To Help Reduce Stigma Around Lung Cancer
HIV infection and lung cancer have little in common from a disease perspective, but the stigma that surrounds both can ...
Citi remains ‘very bullish’ on Gilead HIV franchise
HIV franchise remains its biggest value driver. The firm believes a strong launch of lenacapavir in pre-exposure ...